OSTEOCLAST INHIBITION BY PAMIDRONATE IN METASTATIC PROSTATE-CANCER - A PRELIMINARY-STUDY
OSTEOCLAST INHIBITION BY PAMIDRONATE IN METASTATIC PROSTATE-CANCER - A PRELIMINARY-STUDY
复制标题
DOI：
10.1038/bjc.1991.97
复制
发表时间：
1991-03-01
影响因子：
8.8
通讯作者：
GEORGE, NJR
中科院分区：
文献类型：
--
作者：
CLARKE, NW;HOLBROOK, IB;GEORGE, NJR
25 名接受激素治疗的前列腺癌和转移性骨病患者，至少有 6/12 之前接受过激素治疗，在 6 个月的时间内接受了帕米膦酸二钠 (APD) 静脉输注。 患者每周接受 30 毫克治疗，持续 4 周，然后每月两次，持续 5 个月。 研究期间未进行其他治疗。 研究开始时有疼痛的 17 名患者中有 11 名在研究结束时不再感到疼痛。 帕米膦酸钠使清晨空腹钙排泄量和血清骨钙素显着下降（P < 0.0001），并且 6 个月时 13/20 名可评估患者的尿羟脯氨酸降低。 部分患者的碱性磷酸酶下降，17 名先前进行骨扫描的患者中有 5 名在治疗后稳定 (4) 或消退 (1)。 五名患者升高的酸性磷酸酶水平也有所降低。 结论是，帕米膦酸可能有效缓解某些患者的骨痛，并对转移性前列腺癌异常高的骨转换具有稳定作用。 现在有必要对该化合物进行进一步的对照研究。
Twenty five hormone manipulated patients with prostate cancer and metastatic bone disease, treated at least 6/12 previously by hormone manipulation, were given intravenous infusions of Disodium Pamidronate (APD) over a 6 month period. Patients received 30 mg weekly for 4 weeks then twice monthly for 5 months. No other treatment was administered during study. Eleven of 17 patients with pain at the start of the study were pain free at the end. Fasting morning calcium excretion and serum osteocalcin fell significantly with Pamidronate (P < 0.0001) and urine hydroxyproline was lowered in 13/20 evaluable patients at 6 months. Alkaline phosphatase fell in a proportion of patients and five of 17 patients with previously progressive bone scans stabilised (4) or regressed (1) on treatment. Rising acid phosphatase levels were also lowered in five patients. It is concluded that Pamidronate may be effective in palliating bone pain in some patients and has a stabilising influence on abnormally high bone turnover in metastatic prostate cancer. Further controlled studies of the compound are now warranted.